SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Savient Pharmaceuticals, Inc. Release: New Data Demonstrate KRYSTEXXA®-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life